首页> 外文OA文献 >Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” Breast 41S1 (2018) S11–12

【2h】

Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” Breast 41S1 (2018) S11–12

机译：具有激素受体阳性（HR +）/人表皮生长因子受体2阴性（ABC）的“患者患者患者患者患者患者（PTS）≤50y的静脉曲张（PTS）≤50y：亚组分析2随机阶段3研究“乳房41S1（2018）S11-12

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Massimo Cristofanilli; Nadia Harbeck; Hope S. Rugo; Aurelio Castrellon; Anil Abraham Joy; Sunil Verma; Seock-Ah Im; Shrividya Iyer; Kathy Puyana Theall; Eric Gauthier; Xin Huang; Cynthia Huang Bartlett; Sibylle Loibl; Richard S. Finn;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. EFFICACY plus SAFETY OF PALBOCICLIB (P) IN PATIENTS (PTS) = 50 Y WITH HORMONE RECEPTOR- POSITIVE (HR plus )/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC): SUBGROUP ANALYSIS OF 2 RANDOMIZED PHASE 3 STUDIES [J] . Cristofanilli Massimo, Harbeck Nadia, Rugo Hope, The Breast : . 2018,第Suppla1期

机译：疗效加上患者（PTS）中Palbociclib（P）的疗效加上患者（PTS）＆ = 50°Y，激素受体阳性（HR加）/人表皮生长因子受体2阴性（HER2-）晚期乳腺癌（ABC）：亚组分析 2阶段3研究
2. EFFICACY plus SAFETY OF PALBOCICLIB (P) IN PATIENTS (PTS) = 50 Y WITH HORMONE RECEPTOR- POSITIVE (HR plus )/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC): SUBGROUP ANALYSIS OF 2 RANDOMIZED PHASE 3 STUDIES [J] . Cristofanilli Massimo, Harbeck Nadia, Rugo Hope, The Breast : . 2018,第期

机译：疗效加上患者（PTS）中Palbociclib（P）的疗效加上患者（PTS）＆ = 50°Y，激素受体阳性（HR加）/人表皮生长因子受体2阴性（HER2-）晚期乳腺癌（ABC）：亚组分析 2阶段3研究
3. EFFICACY plus SAFETY OF PALBOCICLIB (P) IN PATIENTS (PTS) = 50 Y WITH HORMONE RECEPTOR- POSITIVE (HR plus )/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC): SUBGROUP ANALYSIS OF 2 RANDOMIZED PHASE 3 STUDIES [J] . Cristofanilli Massimo, Harbeck Nadia, Rugo Hope, The Breast : . 2018,第Suppla1期

机译：疗效加上患者（PTS）中Palbociclib（P）的疗效加上患者（PTS）＆ = 50°Y，激素受体阳性（HR加）/人表皮生长因子受体2阴性（HER2-）晚期乳腺癌（ABC）：亚组分析 2阶段3研究
4. Identification of Human Epidermal Growth Factor Receptor 2 Antagonist In Silico for Breast Cancer Therapy, Derived from Indonesian Phytochemicals [C] . Tuti Ratnasari, Dono indarto, Raden Ajeng Sri Wulandari, International Conference on Biomedical Engineering . 2018

机译：人类表皮生长因子受体2拮抗剂在二氧化硅中用于印尼治疗的印尼植物化学成分的鉴定。
5. Indirect Costs Associated with Human Epidermal Growth Factor Receptor Positive (HER2+) Metastatic Breast Cancer [D] . Wright, Phoebe. 2020

机译：与人表皮生长因子受体阳性（HER2 +）转移性乳腺癌相关的间接成本
6. Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies [O] . Johannes Ettl, Seock-Ah Im, Jungsil Ro, 2020

机译：激素受体阳性/人表皮生长因子受体2阴性的晚期乳腺癌患者palbociclib减量后的血液学不良事件：来自2期和3期随机研究的汇总分析
7. PCN160 COST-EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE COMPARED TO PALBOCICLIB PLUS LETROZOLE IN THE FIRST-LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED OR METASTATIC BREAST CANCER (ABC): A BRAZILIAN PRIVATE PAYER PERSPECTIVE [O] . A. Buehler, H.S.J. Kim, L. Fahham, 2019

机译：PCN160 Ribociclib的成本效果加上Letrozole与Palbociclib加仑唑唑加上患有激素受体阳性/人表皮生长因子受体2阴性（HR + / HER2-）先进或转移性乳腺癌（ABC）的前代妇女：巴西私人付款人的角度

Corrigendum to “Efficacy + safety of palbociclib (P) in patients (pts) ≤50 y with hormone receptor‒positive (HR+)/human epidermal growth factor receptor 2‒negative (HER2–) advanced breast cancer (ABC): Subgroup analysis of 2 randomized phase 3 studies” Breast 41S1 (2018) S11–12

著录项

相似文献

相关主题

期刊订阅